Stunning divergence in equities is a short-term opportunity Stunning divergence in equities is a short-term opportunity Stunning divergence in equities is a short-term opportunity

Stunning divergence in equities is a short-term opportunity

Equities 4 minutes to read
PG
Peter Garnry

Head of Equity Strategy

Summary:  Travel stocks are soaring on good Omicron news and a quicker path to normalisation and the broader commodity sector is still favoured as investors are adding protection against inflation to their portfolios. The flipside is a bloodbath in speculative bubble stocks and themes such as NextGen Medicine and E-commerce. The divergence in just two trading session is stunningly 9.1%-point between the travel and bubble stocks baskets. While there are many arguments for why bubble stocks could fall more, we think the selloff will soon turn into a "buying-the-dip" situation with the market betting on bubble stocks going into the earnings season on the notion that this part of the market will deliver growth surprises.


Speculative growth stocks are continuing their 2021 descent

We are only two full trading sessions into the new year and we are already observing a 9.1%-point difference in performance between the travel basket, helped by the good news on the Omicron variant, and bubble stocks which suffering from the latest move higher in the US 10-year yield and investors continuing their rotating out of speculative growth and adding inflation hedges such as mega caps, financials, energy and mining.

While we think that a better balance between the physical and the online is warranted in the portfolio as inflation will run higher for longer due to physical constraints across energy and metals during the green transformation. But short-term we think a tactical trading opportunity is emerging as many bubble stocks will continue to show high revenue growth, whether they can deliver on operating margin is a different story, and that they will be bought back again by investors. The next couple of weeks could be tough for speculative bubble stocks, but our thinking is that investors will pick them up ahead of the earnings season betting on revenue surprises lifting share price against deteriorating expectations.

Bubble stocks basket

NameMkt Cap (USD mn.)12M Fwd EPS12M Fwd EV/SalesDiff to PT (%)5yr return (%)YTD return (%)
Kuaishou Technology213,499-0.8516.295.5NA-6.2
Sea Ltd140,384-1.2617.3101.5NA-11.6
Airbnb Inc130,635-1.3128.114.0NA2.6
NIO Inc94,795-1.5918.089.8NA-0.3
Snowflake Inc84,570-0.8771.525.7NA-6.9
DoorDash Inc67,743-0.1917.671.9NA-8.7
Roku Inc59,111-0.2623.160.9NA-2.4
Bilibili Inc51,601-4.7618.2159.8NA-12.9
Teladoc Health Inc41,124-0.3020.372.3452.7-0.4
XPeng Inc37,228-2.4115.032.2NA-5.4
Affirm Holdings Inc34,499-0.8939.782.5NA-15.1
BeiGene Ltd34,490-9.7835.871.1699.2-9.1
Unity Software Inc34,299-0.3532.734.5NA-9.3
Plug Power Inc32,156-0.1868.175.52,152.0-0.3
Seagen Inc31,016-0.1115.923.3165.3-1.2
Cloudflare Inc28,050-0.0846.187.0NA-12.6
Splunk Inc27,486-0.2110.844.5106.20.1
MongoDB Inc25,201-0.9834.120.5NA-12.1
Exact Sciences Corp24,752-1.1413.360.7429.92.8
Gaotu Techedu Inc24,455-3.3411.8NANANA
Farfetch Ltd23,465-0.6610.349.1NA-1.1
DraftKings Inc23,186-1.1626.5118.3NA-3.1
GDS Holdings Ltd20,998-0.1518.695.9389.5-13.0
10X Genomics Inc20,458-0.3238.941.5NA-5.1
Argenx SE19,397-10.72105.27.71,718.1-3.9
Alnylam Pharmaceuticals Inc19,214-4.7721.025.3291.3-2.6
Ping An Healthcare and Technology Co Ltd18,942-0.9111.6115.1NA-10.2
Innovent Biologics Inc18,305-0.6124.0140.5NA-17.2
Guardant Health Inc16,826-1.5040.563.9NA-2.0
Zai Lab Ltd15,781-2.5287.5163.3NA-12.1
Kingsoft Cloud Holdings Ltd15,710-2.569.6145.9NA-12.4
Yatsen Holding Ltd15,665-1.1710.766.0NA-7.9
Oak Street Health Inc15,461-0.4611.167.9NA-3.2
C3.ai Inc15,370-0.7969.668.4NA-1.4
Bill.com Holdings Inc15,319-0.1957.465.3NA-12.3
Canopy Growth Corp15,279-0.9024.234.116.73.7
Appian Corp15,229-0.4043.357.5NA1.1
Avalara Inc14,770-0.1621.370.7NA-5.9
Elastic NV14,429-0.4420.650.1NA-5.5
Wolfspeed Inc14,240-0.5921.3NANANA
Aggregate / median1,565,14121.367.0409.7-5.5
Source: Bloomberg and Saxo Group

The market is betting on a totally different car industry

As a follow up to yesterday’s equity note, we extended our commentary on the EV battle in today’s podcast. We failed to cover all our thoughts because we have to be conscious of time, so we expanded further on our thinking in this Twitter thread. At any case, the EV battle this year is one of the most interesting to watch and a defining moment for the car industry. A lot of market value is at risk this year. We forgot in our Twitter thread to elaborate a bit on the car as a platform. The idea for the bulls on Tesla is that 1) the company takes 25% global market share, and 2) cars will become a major digital platform in which you can sell software services on. In that scenario, Tesla could be extremely profitable, but the path to the endpoint is not without risk and while we have seen Volkswagen having difficulties ramping up production to beat Tesla, we do not yet know the dynamics of the remaining large players (Ford, GM, Toyota etc.) entering the EV race at full force.


Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.